Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2
Masatoshi Kudo, Peter R. Galle, Giovanni Brandi, et al.
JHEP Reports (2020) Vol. 3, Iss. 2, pp. 100215-100215
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Hepatocellular carcinoma
Arndt Vogel, Tim Meyer, Gonzalo Sapisochín, et al.
The Lancet (2022) Vol. 400, Iss. 10360, pp. 1345-1362
Closed Access | Times Cited: 1345
ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma
Coşkun Özer Demirtaş, Antonio D’Alessio, Lorenza Rimassa, et al.
JHEP Reports (2021) Vol. 3, Iss. 5, pp. 100347-100347
Open Access | Times Cited: 132
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022
Michel Ducreux, Ghassan K. Abou‐Alfa, Tanios Bekaii‐Saab, et al.
ESMO Open (2023) Vol. 8, Iss. 3, pp. 101567-101567
Open Access | Times Cited: 90
The ALBI score: From liver function in patients with HCC to a general measure of liver function
Hidenori Toyoda, Philip J. Johnson
JHEP Reports (2022) Vol. 4, Iss. 10, pp. 100557-100557
Open Access | Times Cited: 88
The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma
Delia D’Avola, Alessandro Granito, Manuel de la Torre‐Aláez, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 5, pp. 1185-1198
Open Access | Times Cited: 66
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Cancer Reports (2021) Vol. 5, Iss. 2
Open Access | Times Cited: 59
Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities
Carmelo Laface, Palma Fedele, Felicia Maria Maselli, et al.
Cancers (2022) Vol. 14, Iss. 16, pp. 4028-4028
Open Access | Times Cited: 46
Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
Yuka Hayakawa, Kaoru Tsuchiya, Masayuki Kurosaki, et al.
Investigational New Drugs (2021) Vol. 40, Iss. 2, pp. 392-402
Open Access | Times Cited: 50
Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab–bevacizumab
Claudia Campani, Jessica Bamba‐Funck, Bertille Campion, et al.
Liver International (2022) Vol. 43, Iss. 3, pp. 708-717
Closed Access | Times Cited: 32
Albumin-Bilirubin Grade Analyses of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study
Masatoshi Kudo, Richard S. Finn, Ann‐Lii Cheng, et al.
Liver Cancer (2023) Vol. 12, Iss. 5, pp. 479-493
Open Access | Times Cited: 19
First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials
Giuseppe Cabibbo, María Reig, Ciro Celsa, et al.
Liver Cancer (2021) Vol. 11, Iss. 1, pp. 75-84
Open Access | Times Cited: 41
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Hepatology Research (2021) Vol. 52, Iss. 3, pp. 308-316
Open Access | Times Cited: 37
Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy
Masatoshi Kudo
Liver Cancer (2021) Vol. 10, Iss. 2, pp. 85-93
Open Access | Times Cited: 30
Personalized treatment for hepatocellular carcinoma: Current status and future perspectives
Stephen L. Chan, Nathalie Wong, W.K. Lam, et al.
Journal of Gastroenterology and Hepatology (2022) Vol. 37, Iss. 7, pp. 1197-1206
Closed Access | Times Cited: 21
The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis
Takeshi Hatanaka, Atsushi Naganuma, Atsushi Hiraoka, et al.
Cancer Medicine (2022) Vol. 12, Iss. 4, pp. 4259-4269
Open Access | Times Cited: 19
Potential risk of ramucirumab-induced liver failure associated with prior use of oxaliplatin in patients with metastatic gastric cancer: a case report
Sang Hun Lee, Young Jin Choi, Young Mi Seol
Medical Biological Science and Engineering (2025) Vol. 8, Iss. 1, pp. 33-39
Closed Access
Prognostic Value of Changes in Combined Child–Pugh Class and ALBI Grade in Hepatocellular Carcinoma Treated with Transcatheter Intra-Arterial Therapy Plus Targeted Therapy and PD-(L)1 Inhibitors
Xiaoyu Huang, Xiaojing Cao, Yaqing Kong, et al.
Journal of Hepatocellular Carcinoma (2025) Vol. Volume 12, pp. 481-496
Open Access
Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
Hepatology International (2022) Vol. 17, Iss. 1, pp. 86-96
Closed Access | Times Cited: 17
PD-1 Inhibitors Combined with Tyrosine Kinase Inhibitors with or without Hepatic Artery Infusion Chemotherapy for the First-Line Treatment of HBV-Related Advanced Hepatocellular Carcinoma: A Retrospective Study
Dazhen Wang, Zhengfeng Zhang, Liu Yang, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 1157-1170
Open Access | Times Cited: 3
Predictive biomarkers for systemic therapy of hepatocellular carcinoma
Nurbubu T. Moldogazieva, S. P. Zavadskiy, Susanna S. Sologova, et al.
Expert Review of Molecular Diagnostics (2021) Vol. 21, Iss. 11, pp. 1147-1164
Closed Access | Times Cited: 23
Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non–Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2
Richard S. Finn, Thomas Yau, Chih‐Hung Hsu, et al.
The Oncologist (2022) Vol. 27, Iss. 12, pp. e938-e948
Open Access | Times Cited: 15
Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy
Masatoshi Kudo
Cancers (2021) Vol. 13, Iss. 21, pp. 5475-5475
Open Access | Times Cited: 20
The Tumor Microenvironment in Hepatocellular Carcinoma
Katsuya Nagaoka, Yasuhito Tanaka, Okio Hino
(2022), pp. 107-137
Closed Access | Times Cited: 13
Clinical Outcomes of Ramucirumab as Post-treatment Following Atezolizumab/Bevacizumab Combination Therapy in Advanced Hepatocellular Carcinoma
Teiji Kuzuya, Naoto Kawabe, Senju Hashimoto, et al.
Anticancer Research (2022) Vol. 42, Iss. 4, pp. 1905-1910
Open Access | Times Cited: 12
Identification and validation of the N6-methyladenosine RNA methylation regulator ZC3H13 as a novel prognostic marker and potential target for hepatocellular carcinoma
Shuang Wu, Guifang He, Shihai Liu, et al.
International Journal of Medical Sciences (2022) Vol. 19, Iss. 4, pp. 618-630
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top